External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Aarti Drugs’ reported Q3FY24 results stood below our expectations, led by continued reduction in API prices across key therepies and elevated key solvent prices.</li><li>It reported revenue of Rs 606 Cr, down 8.7%/5.6% YoY/QoQ due to a fall in exports and domestic revnue by 28.5% and 4.5% YoY respectively.</li><li>The said de-growth was led by the API segment which de-grew by 13% YoY. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Aarti Drugs’ reported Q3FY24 results stood below our expectations, led by continued reduction in API prices across key therepies and elevated key solvent prices.It reported revenue of Rs 606 Cr, down 8.7%/5.6% YoY/QoQ due to a fall in exports and domestic revnue by 28.5% and 4.5% YoY respectively.The said de-growth was led by the API segment which de-grew by 13% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aarti Drugs Ltd - Continued Reduction in APIs Prices